Market Intelligence, Clinical Progress, and High-Purity Reagents for Metastatic Cancer Therapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for MIEN1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Recombinant Human MIEN1 Protein High purity (>95%), Endotoxin Controlled. Sequence Verified. HEK293 Expressed for native folding. |
View MIEN1 Products |
| Gene Delivery | MIEN1 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and migration assays. |
View MIEN1 Products |
| Benchmark Ab | Anti-MIEN1 Recombinant Antibody Recombinant positive control for expression and localization verification. |
View MIEN1 Products |
| Validator | MIEN1 siRNA Set For knockdown validation in migration and invasion assays. |
View MIEN1 Products |
| Related Target A | ERBB2 (HER2) Frequently co-amplified with MIEN1 on chromosome 17q12; synergistic driver of breast cancer metastasis. |
View ERBB2 Products |
| Related Target B | AKT1 Downstream signaling effector mediated by MIEN1 to promote tumor cell survival and motility. |
View AKT1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intracellular & Peripheral Membrane Localization | HEK293 expressed recombinant protein preserving native post-translation modifications. |
| Target Validation in Migration Assays | Lentivirus for stable overexpression and sequence-verified siRNA for knockdown validation. |
| Lack of Standardized Controls | Recombinant positive control antibodies included for robust Western Blot and IHC assays. |
| Off-Target Toxicity Screening | High-purity homologous panel proteins strictly verified by mass spectrometry. |
Live MIEN1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MIEN1 (Migration and Invasion Enhancer 1, also known as C17orf37) therapeutics is intensifying, with major players shifting focus from traditional targets to novel metastatic regulators. As first-generation therapies targeting the HER2 amplicon reach clinical limits, the next wave of R&D is targeting MIEN1 to directly inhibit tumor cell dissemination and invasion in HER2-positive and triple-negative breast cancers.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Institutions, Emerging Biotechs | Breast Cancer, Prostate Cancer | Binding Affinity Assay (Need sequence-verified recombinant MIEN1) |
| siRNA / Oligonucleotides | RNAi Therapeutics Specialists | Metastatic Solid Tumors | Knockdown Verification (Need validated siRNA set and Lentivirus) |
| Antibody-Drug Conjugates (ADC) | Oncology Biopharma | HER2-Co-amplified Cancers | Internalization Assay (Need high-purity cell-surface target models) |